Investigation of the noncovalent binding mode of covalent proteasome inhibitors around the transition state by combined use of cyclopropylic strain-based conformational restriction and computational modeling

Journal of Medicinal Chemistry

Volumn 56, Issue 14, 2013, Pages 5829-5842

  Kawamura, Shuhei ^a   Unno, Yuka ^b   Tanaka, Motohiro ^c   Sasaki, Takuma ^c   Yamano, Akihito ^d   Hirokawa, Takatsugu ^e   Kameda, Tomoshi ^e   Asai, Akira ^b   Arisawa, Mitsuhiro ^a   Shuto, Satoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

^d RIGAKU CORPORATION   (Japan)

^e NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BELACTOSIN A; COVALENT PROTEASOME INHIBITOR; PROTEASOME INHIBITOR; SALINOSPORAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; DRUG STRUCTURE; IC 50; MOLECULAR DOCKING;

COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; PROTEASOME INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84880856315     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400542h     Document Type: Article

References (63)

1. Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. The resurgence of covalent drugs Nature Rev. Drug Discovery 2011, 10, 307-317
2. Smith, A. J.; Zhang, X.; Leach, A. G.; Houk, K. N. Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins J. Med. Chem. 2009, 52, 225-233
3. Potashman, M. H.; Duggan, M. E. Covalent Modifiers: An Orthogonal Approach to Drug Design J. Med. Chem. 2009, 52, 1231-1246
4. Evans, M. J.; Cravatt, B. F. Mechanism-Based Profiling of Enzyme Families Chem. Rev. 2006, 106, 3279-3301
5. Davis, A. M.; Teague, S. J.; Kleywegt, G. J. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design Angew. Chem., Int. Ed. Engl. 2003, 42, 2718-2736
6. Hajduk, P. J.; Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned Nature Rev. Drug Discovery 2007, 6, 211-219
7. Congreve, M.; Langmead, C. J.; Mason, J. S.; Marshall, F. H. Progress in structure based drug design for G protein-coupled receptors J. Med. Chem. 2011, 54, 4283-4311
8. Adams, J. The proteasome: a suitable antineoplastic target Nature Rev. Cancer 2004, 4, 349-360
9. Kisselev, A. F.; van der Linden, W. A.; Overkleeft, H. S. Proteasome inhibitors: an expanding army attacking a unique target Chem. Biol. 2012, 19, 99-115
10. Dick, L. R.; Fleming, P. E. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy Drug Discovery Today 2010, 15, 243-249
11. Orlowski, R. Z.; Kuhn, D. J. Proteasome inhibitors in cancer therapy: lessons from the first decade Clin. Cancer Res. 2008, 14, 1649-1657
12. Schneekloth, J. S.; Crews, C. M. Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway Curr. Drug Targets 2011, 12, 1581-1594
13. Myung, J.; Kim, K. B.; Crews, C. M. The ubiquitin-proteasome pathway and proteasome inhibitors Med. Res. Rev. 2001, 21, 245-273
14. King, R. W.; Deshaies, R. J.; Peters, J. M.; Kirschner, M. W. How proteolysis drives the cell cycle Science 1996, 274, 1652-1659
15. Fuchs, S. Y. The role of ubiquitin-proteasome pathway in oncogenic signaling Cancer Biol. Ther. 2002, 1, 337-341
16. Chen, J. J.; Lin, F.; Qin, Z. H. The roles of the proteasome pathway in signal transduction and neurodegenerative diseases Neurosci. Bull. 2008, 24, 183-194
17. Vembar, S. S.; Brodsky, J. L. One step at a time: endoplasmic reticulum-associated degradation Nature Rev. Mol. Cell Biol. 2008, 9, 944-957
18. Ron, D.; Walter, P. Signal integration in the endoplasmic reticulum unfolded protein response Nature Rev. Mol. Cell Biol. 2007, 8, 519-529
19. Hiller, M. M.; Finger, A.; Schweiger, M.; Wolf, D. H. ER degradation of a misfolded luminal protein by the cytosolic ubiquitin-proteasome pathway Science 1996, 273, 1725-1728
20. Paramore, A.; Frantz, S. Bortezomib Nature Rev. Drug Discovery 2003, 2, 611-612
21. Bross, P. F.; Kane, R.; Farrell, A. T.; Abraham, S.; Benson, K.; Brower, M. E.; Bradley, S.; Gobburu, J. V.; Goheer, A.; Lee, S. L.; Leighton, J.; Liang, C. Y.; Lostritto, R. T.; McGuinn, W. D.; Morse, D. E.; Rahman, A.; Rosario, L. A.; Verbois, S. L.; Williams, G.; Wang, Y. C.; Pazdur, R. Approval summary for bortezomib for injection in the treatment of multiple myeloma Clin. Cancer Res. 2004, 10, 3954-3964
22. Kane, R. C.; Farrell, A. T.; Sridhara, R.; Pazdur, R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy Clin. Cancer Res. 2006, 12, 2955-2960
23. Abraham, J. Carfilzomib and bortezomib therapy in patients with multiple myeloma Community Oncol. 2012, 9, 278-282
24. Asai, A.; Hasegawa, A.; Ochiai, K.; Yamashita, Y.; Mizukami, T. Belactosin A, a novel antitumor antibiotic acting on cyclin/CDK mediated cell cycle regulation, produced by Streptomyces sp J. Antibiot. 2000, 53, 81-83
25. Asai, A.; Tsujita, T.; Sharma, S. V.; Yamashita, Y.; Akinaga, S.; Funakoshi, M.; Kobayashi, H.; Mizukami, T. A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay Biochem. Pharmacol. 2004, 67, 227-234
26. Groll, M.; Larionov, O. V.; Huber, R.; De Meijere, A. Inhibitor-binding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 4576-4579
27. Yoshida, K.; Yamaguchi, K.; Sone, T.; Unno, Y.; Asai, A.; Yokosawa, H.; Matsuda, A.; Arisawa, M.; Shuto, S. Synthesis of 2,3- and 3,4-methanoamino acid equivalents with stereochemical diversity and their conversion into the tripeptide proteasome inhibitor belactosin a and its highly potent cis -cyclopropane stereoisomer Org. Lett. 2008, 10, 3571-3574
28. Yoshida, K.; Yamaguchi, K.; Mizuno, A.; Unno, Y.; Asai, A.; Sone, T.; Yokosawa, H.; Matsuda, A.; Arisawa, M.; Shuto, S. Three-dimensional structure-activity relationship study of belactosin A and its stereo- and regioisomers: development of potent proteasome inhibitors by a stereochemical diversity-oriented strategy Org. Biomol. Chem. 2009, 7, 1868-1877
29. Kawamura, S.; Unno, Y.; List, A.; Mizuno, A.; Tanaka, M.; Sasaki, T.; Arisawa, M.; Asai, A.; Groll, M.; Shuto, S. Potent Proteasome Inhibitors Derived from the Unnatural cis -Cyclopropane Isomer of Belactosin A: Synthesis, Biological Activity, and Mode of Action J. Med. Chem. 2013, 56, 3689-3700
30. Parthasarathy, S.; Murthy, M. Protein thermal stability: insights from atomic displacement parameters (B values) Protein Eng. 2000, 13, 9-13
31. Yuan, Z.; Zhao, J.; Wang, Z.-X. Flexibility analysis of enzyme active sites by crystallographic temperature factors Protein Eng. 2003, 16, 109-114
32. Radivojac, P.; Obradovic, Z.; Smith, D. K.; Zhu, G.; Vucetic, S.; Brown, C. J.; Lawson, J. D.; Dunker, A. K. Protein flexibility and intrinsic disorder Protein Sci. 2009, 13, 71-80
33. Kozikowski, A. P. Drug Design for Neuroscience; Raven Press: New York, 1993
34. Silverman, R. B. The Organic Chemistry of Drug Design and Drug Action; Academic Press: New York, 2004.
35. Wermuth, C. G. The Practice of Medicinal Chemistry; Academic Press: New York, 2008.
36. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications Nature Rev. Drug Discovery 2004, 3, 935-949
37. Taylor, R. D.; Jewsbury, P. J.; Essex, J. W. A review of protein-small molecule docking methods J. Comput.-Aided Mol. Des. 2002, 16, 151-166
38. Armstrong, P. D.; Cannon, J. G.; Long, J. P. Conformationally Rigid Analogues of Acetylcholine Nature 1968, 220, 65-66
39. Kazuta, Y.; Hirano, K.; Natsume, K.; Yamada, S.; Kimura, R.; Matsumoto, S.; Furuichi, K.; Matsuda, A.; Shuto, S. Cyclopropane-based conformational restriction of histamine. (1 S,2 S)-2-(2-aminoethyl)-1-(1 H -imidazol-4-yl) cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis -cyclopropane structure J. Med. Chem. 2003, 46, 1980-1988
40. Watanabe, M.; Kazuta, Y.; Hayashi, H.; Yamada, S.; Matsuda, A.; Shuto, S. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure J. Med. Chem. 2006, 49, 5587-5596
41. Watanabe, M.; Kobayashi, T.; Hirokawa, T.; Yoshida, A.; Ito, Y.; Yamada, S.; Orimoto, N.; Yamasaki, Y.; Arisawa, M.; Shuto, S. Cyclopropane-based stereochemical diversity-oriented conformational restriction strategy: histamine H3 and/or H4 receptor ligands with the 2,3-methanobutane backbone Org. Biomol. Chem. 2012, 10, 736-745
42. Shuto, S.; Ono, S.; Hase, Y.; Kamiyama, N.; Takada, H.; Yamasihita, K.; Matsuda, A. Conformational restriction by repulsion between adjacent substituents on a cyclopropane ring: Design and enantioselective synthesis of 1-phenyl-2-(1-aminoalkyl)- N, N -diethylcyclopropanecarboxamide as potent NMDA receptor antagonists J. Org. Chem. 1996, 61, 915-923
43. Shuto, S.; Ono, S.; Hase, Y.; Ueno, Y.; Noguchi, T.; Yoshii, K.; Matsuda, A. Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1 S,2 R)-1-phenyl-2-[(S)-1-aminopropyl]- N, N - diethylcyclopropanecarboxamide, an efficient noncompetitive N -methyl- d -aspartic acid receptor antagonist J. Med. Chem. 1996, 39, 4844-4852
44. Shuto, S.; Ono, S.; Imoto, H.; Yoshii, K.; Matsuda, A. Synthesis and biological activity of conformationally restricted analogues of milnacipran: (1 S,2 R)-1-phenyl-2-[(R)-1-amino-2-propynyl]- N, N -diethylcyclopropanecarboxamide is a novel class of NMDA receptor channel blocker J. Med. Chem. 1998, 41, 3507-3514
45. Ono, S.; Ogawa, K.; Yamashita, K.; Yamamoto, T.; Kazuta, Y.; Matsuda, A.; Shuto, S. Conformational analysis of the NMDA receptor antagonist (1 S,2 R)-1-phenyl-2-[(S)-1-aminopropyl]- N, N -diethylcyclopropanecarboxamide (PPDC) designed by a novel conformational restriction method based on the structural feature of cyclopropane ring Chem. Pharm. Bull. 2002, 50, 966-968
46. Yamaguchi, K.; Kazuta, Y.; Hirano, K.; Yamada, S.; Matsuda, A.; Shuto, S. Synthesis of 1-arylpiperazyl-2-phenylcyclopropanes designed as antidopaminergic agents: cyclopropane-based conformationally restricted analogs of haloperidol Bioorg. Med. Chem. 2008, 16, 8875-8881
47. Watanabe, M.; Hirokawa, T.; Kobayashi, T.; Yoshida, A.; Ito, Y.; Yamada, S.; Orimoto, N.; Yamasaki, Y.; Arisawa, M.; Shuto, S. Investigation of the bioactive conformation of histamine H3 receptor antagonists by the cyclopropylic strain-based conformational restriction strategy J. Med. Chem. 2010, 53, 3585-3593
48. Groll, M.; McArthur, K. A.; Macherla, V. R.; Manam, R. R.; Potts, B. C. Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition J. Med. Chem. 2009, 52, 5420-5428
49. Feling, R. H.; Buchanan, G. O.; Mincer, T. J.; Kauffman, C. A.; Jensen, P. R.; Fenical, W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora Angew. Chem., Int. Ed. Engl. 2003, 42, 355-357
50. Macherla, V. R.; Mitchell, S. S.; Manam, R. R.; Reed, K. A.; Chao, T. H.; Nicholson, B.; Deyanat-Yazdi, G.; Mai, B.; Jensen, P. R.; Fenical, W. F.; Neuteboom, S. T.; Lam, K. S.; Palladino, M. A.; Potts, B. C. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor J. Med. Chem. 2005, 48, 3684-3687
51. Groll, M.; Huber, R.; Potts, B. C. M. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding J. Am. Chem. Soc. 2006, 128, 5136-5141
52. Guimarães, C. MM-GB/SA Rescoring of Docking Poses Methods Mol. Biol. 2012, 819, 255
53. Guimarães, C. R. W.; Cardozo, M. MM-GB/SA Rescoring of Docking Poses in Structure-Based Lead Optimization J. Chem. Inf. Model. 2008, 48, 958-970
54. Lyne, P. D.; Lamb, M. L.; Saeh, J. C. Accurate Prediction of the Relative Potencies of Members of a Series of Kinase Inhibitors Using Molecular Docking and MM-GBSA Scoring J. Med. Chem. 2006, 49, 4805-4808
55. Nett, M.; Gulder, T. A. M.; Kale, A. J.; Hughes, C. C.; Moore, B. S. Function-oriented biosynthesis of β-lactone proteasome inhibitors in Salinispora tropica J. Med. Chem. 2009, 52, 6163-6167
56. Manam, R. R.; McArthur, K. A.; Chao, T. H.; Weiss, J.; Ali, J. A.; Palombella, V. J.; Groll, M.; Lloyd, G. K.; Palladino, M. A.; Neuteboom, S. T. C. Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides J. Med. Chem. 2008, 51, 6711-6724
57. Evans, D. A.; Wu, L. D.; Wiener, J. J. M.; Johnson, J. S.; Ripin, D. H. B.; Tedrow, J. S. A General Method for the Synthesis of Enantiomerically Pure β-Substituted, β-Amino Acids through α-Substituted Succinic Acid Derivatives J. Org. Chem. 1999, 64, 6411-6417
58. Kazuta, Y.; Matsuda, A.; Shuto, S. Development of versatile cis-and trans -dicarbon-substituted chiral cyclopropane units: synthesis of (1 S,2 R)- and (1 R,2 R)-2-aminomethyl-1-(1H-imidazol-4-yl)cyclopropanes and their enantiomers as conformationally restricted analogues of histamine J. Org. Chem. 2002, 67, 1669-1677
59. Cogan, D. A.; Liu, G.; Ellman, J. Asymmetric synthesis of chiral amines by highly diastereoselective 1,2-additions of organometallic reagents to N-tert -butanesulfinyl imines Tetrahedron 1999, 55, 8883-8904
60. Yabuuchi, T.; Kusumi, T. Phenylglycine methyl ester, a useful tool for absolute configuration determination of various chiral carboxylic acids J. Org. Chem. 2000, 65, 397-404
61. Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. High-field FT NMR application of Mosher's method. The absolute configurations of marine terpenoids J. Am. Chem. Soc. 1991, 113, 4092-4096
62. Kusumi, T.; Fukushima, T.; Ohtani, I.; Kakisawa, H. Elucidation of the absolute configurations of amino acids and amines by the modified mosher's method Tetrahedron Lett. 1991, 32, 2939-2942
63. Armstrong, A.; Scutt, J. N. Total synthesis of (+)-belactosin A Chem. Commun. 2004, 510-511